




SUPPLEMENTARY INFORMATION

Satb1 regulates the effector program of encephalitogenic tissue Th17 cells
in chronic inflammation


Keiko Yasuda, Yohko Kitagawa, Ryoji Kawakami, Yoshitaka Isaka, Hitomi Watanabe, Gen Kondoh,
Terumi Kohwi-Shigematsu, Shimon Sakaguchi, Keiji Hirota

a**b**

Supplementary Figure 1. Up-regulation of *Satb1* mRNA under Th17 culture conditions. a) qPCR of Th0, Th1, Th2, Th17, and iTReg for *Satb1*, *Ifng*, *Il4*, *Il17a* and *Foxp3* mRNA. Flow cytometry of the indicated Th subsets and iTReg for intracellular IFN- γ , IL-4, IL-17 and Foxp3 expression. The bar graphs show the mean \pm s.d. (n=3). **b)** qPCR of Th0 and Th17 for the kinetics of *Satb1* mRNA. The results are representative of three independent experiments.





Supplementary Figure 2. Normal phenotypes and functions of *Satb1*-deficient non-pathogenic Th17 cells in Peyer's patches. **a)** Flow cytometry of the PPs eYFP⁺ CD4⁺ T cells from *Il17a*^{Cre} *R26R*^{eYFP} *Satb1*^{wt/wt} (control) and *Il17a*^{Cre} *R26R*^{eYFP} *Satb1*^{fl/fl} (*Th17*^{*Satb1*KO} mice) for intracellular IL-17A and GM-CSF expression. The frequencies of IL-17⁺ and GM-CSF⁺ in eYFP⁺ CD4⁺ T cells are shown. **b)** Flow cytometry of the PPs eYFP⁺ CD4⁺ T cells as in (a) for PD-1 expression. **c)** qPCR of the expression of *Bhlhe40* in the PPs eYFP⁺ CD4⁺ T cells of control or *Th17*^{*Satb1*KO} mice. The bar graphs (a and c) show the mean ± s.d. (n=3). The results are representative of at least three independent experiments (a-c). **d)** RNA-seq analysis of the PPs eYFP⁺ CD4⁺ T cells from control and *Th17*^{*Satb1*KO} mice. The data are presented as fragments per kilo base of exon per million mapped fragments (FPKM). The bar graphs show the mean ± s.d. (WT control; n=3, *Satb1* CKO; n=4).




Supplementary Figure 3. Cytokine production and the expression of surface markers by Th17 cells.

a) Cytokine concentrations in the culture supernatant of re-stimulated Th17 cells are shown. eYFP⁺ Th17 cells were sorted from the spleen of control or Th17^{Satb1KO} mice at the peak of EAE. Sorted Th17 cells were re-stimulated with BMDCs in the presence of MOG₃₅₋₅₅ peptide (50 μg/ml) for 24 hours. **b)** Flow cytometry of splenic eYFP⁺ CD4⁺ T cells (day14 after EAE induction) for the expression of PD-1, CTLA-4, LAG3, TIGIT, and Tim3. **c)** Cytokine concentrations in the culture supernatant of re-stimulated Th17 cells are shown. eYFP⁺ Th17 cells were sorted from the spinal cord of control or Th17^{Satb1KO} mice at the peak of EAE. Sorted Th17 cells were re-stimulated with BMDCs in the presence of MOG₃₅₋₅₅ peptide (50 μg/ml) with or without the PD-1 antibody (20 μg/ml) for 24 hours. The bar graphs (**a** and **c**) show the mean ± s.d. (n=3). **P*<0.05; ***P*<0.001. (two-tailed unpaired Student's *t*-test)




Supplementary Figure 4. Analysis of the Satb1 binding sites at the *Csf2*, *Hif1a*, *Ikzf3*, *Nfkbiz* and *Prdm1* loci.

a) Flow cytometry of *in vitro* polarized Th17 cells from control and Th17^{Satb1KO} mice for PD-1 expression. The bar graphs show the mean \pm s.d. (n=3). ** $P < 0.001$ (two-tailed unpaired Student's *t*-test). **b)** ChIP-seq analyses of Satb1 binding and H3K27ac modification at the *Csf2*, *Hif1a*, *Ikzf3*, *Nfkbiz* and *Prdm1* loci in *in vitro* polarized Th0 or eYFP⁺ Th17 cells.



Supplementary Figure 5. PD-1 expression by Th17 cells from PPs and inflamed spinal cord.

a) Flow cytometry of eYFP⁺ CD4⁺ T cells from PPs and the spinal cord 14 days after EAE induction for the expression of PD-1. **b)** qPCR of *Pdccl1* mRNA expression in re-stimulated Th17 cells are shown. eYFP⁺ Th17 cells were sorted from the draining LNs of EAE mice on day7 and then re-stimulated with CD3/CD28 Dynabeads in the presence TGFβ for 24 hours. The bar graphs (**a** and **b**) show the mean ± s.d. (n=3). The results are representative of three independent experiments. * $P < 0.05$; ** $P < 0.001$. (two-tailed unpaired Student's *t*-test).



Supplementary Figure 6. Gating strategies. **a)** Gating strategies to sort naïve ($CD44^{\text{low}} CD25^- CD4^+$) T cells from C57BL/6 WT mice presented on **Fig. 1a**. The same strategy was used to sort naïve T cells presented on **Fig. 1, 5, 7, Supplementary Fig. 1** and **Supplementary Fig. 4**. **b)** Gating strategies to sort pathogenic eYFP⁺ Th17 cells from the spinal cord after EAE induction from control mice presented on **Fig. 2g**. The same strategy was used for the analysis and sorting of pathogenic Th17 cells in **Fig. 2, 3, 4, 5, 6, Supplementary Fig. 3, Supplementary Fig. 5** and **Table 2**. **c)** Gating strategies for non-pathogenic eYFP⁺ Th17 cells from the PPs of non-immunized control mice presented on **Fig. 1a**. The same strategy was used for the analysis and sorting of non-pathogenic Th17 cells in **Fig. 2, 4, 5, Supplementary Fig. 2, Supplementary Fig. 5**, and **Table 2**. **d)** Gating strategies to sort NGFR⁺ CD4⁺ T cells after retroviral transduction presented on **Fig. 5c**. The same strategy was used for sorting of NGFR⁺ CD4⁺ T cells in **Fig. 5**.